Stocks and Investing
Stocks and Investing
Fri, April 23, 2021
[ 12:00 AM ] - WOPRAI
Thu, April 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, April 21, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Initiated (ACRS) at Strong Buy and Held Target at $40 on, Apr 21st, 2021
Raghuram Selvaraju of HC Wainwright & Co., Initiated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $40 on, Apr 21st, 2021.
Raghuram has made no other calls on ACRS in the last 4 months.
There is 1 other peer that has a rating on ACRS. Out of the 1 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Thomas Smith of "SVB Leerink" Maintained at Buy with Increased Target to $26 on, Thursday, March 4th, 2021
Contributing Sources